Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.
Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.
